What question did this study set out to answer?

The aim is to establish a humanized mouse model for evaluating bispecific antibodies in hemophilia A.

June 13, 2026Blood AdvancesOpen Access

A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates hemostatic effects of bispecific antibodies in a novel hemophilia A mouse model, suggesting new therapeutic potential.

The aim is to establish a humanized mouse model for evaluating bispecific antibodies in hemophilia A.
Created hFIX/hFX double knock-in congenital hemophilia A mice by replacing mouse genes with human homologs.
Conducted thrombin generation assays to assess the function of recombinant human FVIII and emicizumab.
Performed tail-clip assays to explore the hemostatic effects of treatments.
HuHA mice express human FIX and FX at levels comparable to human plasma.
Thrombin generation assays showed dose-dependent improvement with rhFVIII and emicizumab.
Tail-clip assays indicated potential hemostatic effects, albeit with model limitations.

Watanabe et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates hemostatic effects of bispecific antibodies in a novel hemophilia A mouse model, suggesting new therapeutic potential.